Strategies to Mitigate the Rising Cancer Cost Burden

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the increasing cost burden of cancer therapies and future strategies for mitigating costs. 


If you’re looking at it from a payer’s perspective, we see payers really paying a lot of attention to the oncology space, particularly self-administered oncology, looking at the criteria of use for those. You look at CML. Now we have patients who are living longer. This has become a chronic disease for these patients. So we see some specialty generics coming to space, imatinib for CML. You see some benefits across the entire space with overall cost of therapy with these specialty generics.

Most Popular

Related Articles

Keep an eye out for these specialty pipeline medications in 2019.
Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.
This is the first time an anti-PD-1 therapy has demonstrated a survival benefit in this patient population.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.